Therapeutic potential of extracellular vesicles derived from tetramethylpyrazine-preconditioned mesenchymal stem cells in a mouse model of aplastic anemia

Acquired aplastic anemia (AA) is a severe hematological disorder characterized primarily by bone marrow (BM) failure and hypoplastic myelopoiesis. Extracellular vesicles (EVs) secreted by mesenchymal stem cells (MSCs) have emerged as a promising therapeutic approach for hematopoietic disorders. In the present study, MSCs‑derived EVs were isolated by differential ultracentrifugation after in vitro stimulation of MSCs with tetramethylpyrazine (TMP); EV identity was verified by nanoparticle tracking analysis, transmission electron microscopy and western blotting for surface markers. An AA mouse model was subsequently established via cyclophosphamide combined with busulfan conditioning to evaluate the therapeutic effects of EVs on BM hematopoiesis. Western blotting was used to detect the expression of signaling‑related proteins. Flow cytometry was performed to quantify T helper 17 (Th17) and regulatory T (Treg) cell proportions. The levels of hematopoietic cytokines were determined using an ELISA assay. And BM hematopoietic function was evaluated by blood cell counting and CD34 immunohistochemistry staining. TMP stimulation markedly increased EVs secretion into MSCs culture supernatants, potentially through the Rab27a/mammalian target of rapamycin complex 1 signaling axis. In vivo, EVs treatment significantly increased peripheral blood cell and BM nucleated cell counts, improved spleen indices and restored the disrupted Th17/Treg immune balance in AA mice. Moreover, EVs treatment effectively upregulated the expression of key hematopoietic regulators, including granulocyte‑macrophage colony‑stimulating factor, thrombopoietin and erythropoietin. In conclusion, the present findings support the potential of MSC‑derived EVs as a treatment for AA by improving hematopoietic function.

Authors

Institutions

Publication Details

Journal
Experimental and Therapeutic Medicine
Published
2026-11-16
DOI
https://doi.org/10.3892/etm.2026.13358
Primary Topic
Extracellular vesicles in disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Therapeutic potential of extracellular vesicles derived from tetramethylpyrazine-preconditioned mesenchymal stem cells in a mouse model of aplastic anemia

Ling Kui, Fengqi Duan, Peining Dou, Lixuan Chen et al.
1 links
Experimental and Therapeutic Medicine
Extracellular vesicles in disease
article

Therapeutic potential of extracellular vesicles derived from tetramethylpyrazine-preconditioned mesenchymal stem cells in a mouse model of aplastic anemia

Ling Kui, Fengqi Duan, Peining Dou, Lixuan Chen, Yang Xiao, Xiaoyan Sun, Jian Zhang, Zenghui Liu, Xiaomin Zhang
article en

Abstract

Acquired aplastic anemia (AA) is a severe hematological disorder characterized primarily by bone marrow (BM) failure and hypoplastic myelopoiesis. Extracellular vesicles (EVs) secreted by mesenchymal stem cells (MSCs) have emerged as a promising therapeutic approach for hematopoietic disorders. In the present study, MSCs‑derived EVs were isolated by differential ultracentrifugation after in vitro stimulation of MSCs with tetramethylpyrazine (TMP); EV identity was verified by nanoparticle tracking analysis, transmission electron microscopy and western blotting for surface markers. An AA mouse model was subsequently established via cyclophosphamide combined with busulfan conditioning to evaluate the therapeutic effects of EVs on BM hematopoiesis. Western blotting was used to detect the expression of signaling‑related proteins. Flow cytometry was performed to quantify T helper 17 (Th17) and regulatory T (Treg) cell proportions. The levels of hematopoietic cytokines were determined using an ELISA assay. And BM hematopoietic function was evaluated by blood cell counting and CD34 immunohistochemistry staining. TMP stimulation markedly increased EVs secretion into MSCs culture supernatants, potentially through the Rab27a/mammalian target of rapamycin complex 1 signaling axis. In vivo, EVs treatment significantly increased peripheral blood cell and BM nucleated cell counts, improved spleen indices and restored the disrupted Th17/Treg immune balance in AA mice. Moreover, EVs treatment effectively upregulated the expression of key hematopoietic regulators, including granulocyte‑macrophage colony‑stimulating factor, thrombopoietin and erythropoietin. In conclusion, the present findings support the potential of MSC‑derived EVs as a treatment for AA by improving hematopoietic function.

Experimental and Therapeutic MedicineVol. 33(1)
Guangzhou University of Chinese Medicine (CN), Sun Yat-sen University (CN), Shenzhen University (CN), Chinese Academy of Sciences (CN), The Seventh Affiliated Hospital of Sun Yat-sen University (CN), First Affiliated Hospital of Guangzhou University of Chinese Medicine (CN), Guangzhou Development Zone Hospital (CN), Shenzhen Institutes of Advanced Technology (CN), Southern Medical University (CN)
Good health and well-being
Extracellular vesicles in disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon